-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, G2AlHrgMZgDincs7oBdT5lGHjLawB1zYBpnQdh0GJsuVgjvccQWw0Hhe2uyWTZjn dVwQ7AMZD82ik+EUWJM2fg== 0001017062-01-500175.txt : 20010503 0001017062-01-500175.hdr.sgml : 20010503 ACCESSION NUMBER: 0001017062-01-500175 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20010430 ITEM INFORMATION: FILED AS OF DATE: 20010502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CORTEX PHARMACEUTICALS INC/DE/ CENTRAL INDEX KEY: 0000849636 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330303583 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-17951 FILM NUMBER: 1620095 BUSINESS ADDRESS: STREET 1: 15241 BARRANCA PKWY CITY: IRVINE STATE: CA ZIP: 92718 BUSINESS PHONE: 7147273157 MAIL ADDRESS: STREET 2: 15241 BARRANCA PARKWAY CITY: IRVINE STATE: CA ZIP: 92718 8-K 1 d8k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ------------------ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 APRIL 30, 2001 --------------------------------- (Date of earliest event reported) CORTEX PHARMACEUTICALS, INC. -------------------------------------------------- (Exact name of Registrant as specified in charter) DELAWARE 0-17951 33-0303583 - -------------------------------------------------------------------------------- (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 15241 BARRANCA PARKWAY IRVINE, CALIFORNIA 92618 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) (949) 727-3157 ---------------------------------------------------- (Registrant's telephone number, including area code) NOT APPLICABLE --------------------------------------------------------------- (Former name or former address, if changed, since last report.) Page 1 of 2 Pages Exhibit Index on Page 2 ITEM 5. OTHER EVENTS. On April 30, 2001, Cortex Pharmaceuticals, Inc. announced that it was approved for trading on the American Stock Exchange. It will trade under the symbol COR. The press release is being filed herewith as Exhibit 99.1 to this Current Report. The Exhibit is incorporated herein by reference. EXHIBIT NUMBER DESCRIPTION ------- ----------- 99.1 Press Release dated April 30, 2001. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: MAY 2, 2001 CORTEX PHARMACEUTICALS, INC. /s/ MARIA S. MESSINGER ------------------------------------- Maria S. Messinger Vice President, Chief Financial Officer and Corporate Secretary (Chief Accounting Officer) EXHIBIT INDEX EXHIBIT NUMBER DESCRIPTION PAGE NUMBER - -------------- ----------- ----------- 99.1 Press Release dated April 30, 2001. 2 EX-99.1 2 dex991.txt PRESS RELEASE EXHIBIT 99.1 Press Release Contacts: Vincent F. Simmon, Ph.D. Bruce Russell President and CEO Investor Relations Cortex Pharmaceuticals, Inc. Russell Communications Group (949) 727-3157 (310) 216-1414 Cortex to Begin Trading on The American Stock Exchange --NEW SYMBOL WILL BE "COR"-- Irvine, CA, April 30, 2001 - Cortex Pharmaceuticals, Inc. (OTCBB: CORX) announced today that its shares of common stock had been approved for listing on The American Stock Exchange. The shares are expected to begin trading on the Exchange during the week of May 7, 2001, under the ticker symbol COR. The Company's shares will cease trading on the Over the Counter Bulletin Board on the same date. "We are very pleased to join The American Stock Exchange," said Vincent F. Simmon, Ph.D., President and Chief Executive Officer of Cortex. "There are many benefits of an exchange listing, including a substantially enhanced visibility. Through its investor relations programs and services, we believe that listing on the AMEX will help us build long-term value for our shareholders. Currently our share price is not quoted in daily newspapers because we are a bulletin board stock. In addition, many investment funds that might have an interest in Cortex are not permitted to take positions in stocks that are not listed on one of the major exchanges." Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called Ampakine compounds, which act to increase the strength of signals at connections between brain cells. The weakening or loss of these connections is thought to be responsible for memory difficulties from Alzheimer's disease and to contribute to cognitive dysfunction in schizophrenia. A recently completed study with Ampakine CX516 in patients with schizophrenia indicated improvement in a number of symptoms also common to patients with ADHD. Cortex has alliances with NV Organon for the potential treatment of schizophrenia and depression, and with Shire Pharmaceuticals Group for the evaluation and potential licensing of the Ampakine technology and molecules as a treatment for attention deficit hyperactivity disorder (ADHD). Cortex has licensed the Ampakine technology in Europe and Asia to Les Laboratoires Servier of Paris for a number of age and disease related neurodegenerative conditions including Alzheimer's disease, Mild Cognitive Impairment and dementias associated with diseases such as multiple sclerosis and Parkinson's disease. Website: http://www.cortexpharm.com/ --------------------------- Note -- This press release contains forward-looking statements concerning the Company's research and development activities and business development plans. Actual results may differ materially, depending on a number of risk factors, including the risks that the Company may be unable to secure additional capital needed to continue its operations; that the Company may be unable to arrive at corporate partnerships with additional pharmaceutical companies on acceptable terms and therefore be required to independently fund clinical development of Ampakine molecules through the sale of additional equity securities or otherwise; that the Company's proposed products may at any time be found to be toxic or ineffective for any or all of their proposed indications; that competitors may challenge or design around the Company's patents or develop competing technologies; and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company's Securities and Exchange Commission filings, the Company's proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. The Ampakine molecules are investigational drugs and have not yet been shown to have efficacy in the treatment of any disease. # # # # # -----END PRIVACY-ENHANCED MESSAGE-----